- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05062902
A Novel Medical System for Quantitative Diagnosis and Personalized Precision Botulinum Neurotoxin Injection in Chronic Pelvic Pain Management
An Novel Medical System for Quantitative Diagnosis and Personalized Precision Botulinum Neurotoxin Injection in Chronic Pelvic Pain Management
Study Overview
Status
Detailed Description
The management of pelvic floor overactivity (PFOA) using focal BoNT injection has been gaining clinical interest. Evidence has shown that BoNT injections to the levator ani in patients with CPP generated a greater than 50% improvement in symptoms at least 72% of the time, suggesting a promising efficacy of BoNT therapy. The current clinical standard for BoNT injection employs a fixed injection template or the manual palpation of a contracted muscle, followed by an injection towards the palpating finger. As such, the injection is highly subjective, operator-dependent, variable, and not tailored to individual patients, which may lead to inconsistent outcomes. Trigger point targeted injections have been practiced for many years worldwide, yet a recent randomized controlled trial reported no significant difference in outcome between trigger point targeted BoNT injections versus a saline placebo. Furthermore, it has also been reported that neuromuscular junction (NMJ) and trigger points are distributed in well-defined separate areas with a distance of approximately 10 mm apart. It has also been shown that BoNT injections made 10 mm away from the NMJ can reduce the efficacy of BoNT by 46%. Therefore, injections targeted at the trigger point may, in turn, compromise therapeutic efficacy.
The rationale of this study is that BoNT acts at the NMJ, where the neuromuscular junctions are densely located. By specifying the muscle(s) responsible for the pelvic floor overactivity, and the offending NMJ using high density surface electromyography (HD-sEMG), BoNT can be injected with greater accuracy and objectivity to optimize treatment efficacy. The investigators aim to test the hypothesis that interstitial cystitis patients in the guided injection arm will demonstrate lower hypertonic metrics and improved quality of life. The purpose of this study is to provide preliminary evidence supporting the use of HD-sEMG and NMJ mapping to guide BoNT efficacy.
Study Type
Enrollment (Estimated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Nicholas C Dias, PhD
- Phone Number: 2816581953
- Email: nickdias@hillmedgroup.com
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine
-
Contact:
- Christopher P Smith, MD, MBA, MSS
- Phone Number: 713-798-4001
- Email: cps@bcm.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Inclusion criteria for interstitial cystitis/bladder pain syndrome (IC/BPS) patients will be:
- Woman aged 18 to 60.
- Have a clinical diagnosis of IC/BPS.
- Pain, pressure, or discomfort in the bladder and/or pelvic area for the past 6 months or more, associated with lower urinary tract symptoms (such as frequency of urination), in the absence of other explanation of the symptoms (e.g., urinary tract infection).
- Myofascial pain diagnosed with palpable contracted muscle fibers.
- Pelvic muscle tenderness by assessment of pelvic floor muscles on digital pelvic examination.
- Pelvic floor hypertonicity (PFH), measured using vaginal manometry (pressure > 35 cm∙H2O).
- Ability to provide informed consent.
Exclusion Criteria:
Exclusion criteria consist of the following:
- History of pelvic malignancy and sexually transmitted diseases.
- Bleeding disorder such as coagulopathy
- History of neurological disorders, such as spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis or myasthenia gravis.
- Pregnancy, breast feeding or desiring for pregnancy in the coming year.
- Subjects with history of pelvic surgery (e.g., pain from mid-urethral sling or pelvic mesh),
- Pelvic malignancy (urinary tract, gynecologic, gastrointestinal)
- Active fistula
- Radiation cystitis
- Cyclophosphamide cystitis
- Pre-existing anorectal disorders
- Infections near the injection sites
- History of drug or alcohol abuse
- Hypersensitivity to BoNT
- Steroids or hormone usage will be carefully considered by the research team for inclusion.
Participants with on-going BoNT therapies will not be screened until the complete drug washout is confirmed.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Template Injection
For the standard template injection, 200 units of BoNT diluted in 6mL of preservative saline will be prepared.
1/4 of the prepared BoNT solution will be administered to each of the pubococcygeus and puborectalis muscle at 5 and 7 o'clock position, respectively.
The index finger will be used for palpation as the 20-gauge spinal needle with a trumpet guide (i.e.
paracervical block kit) piercing through the vaginal mucosa to the intended muscle groups.
The syringe will be withdrawn before each injection to avoid intravascular injection.
|
Botulinum neurotoxin will be injected into the pelvic floor muscles following either a standard template (standard injection arm), or guided using high-density surface EMG (guided arm).
|
Experimental: Guided Injection
For the guided injection, pelvic floor injections (total of 4) will be made to the pubococcygeus and puborectalis muscles each, at NMJ locations (1.5 ml per site), at patient-specific locations and depths identified from vaginal HD-sEMG recordings.
NMJ mappings will be generated for each participant.
The channel locations will provide angle measurements for each NMJ.
The device will calculate these parameters based on acquired HD-sEMG.
The index finger will be used for palpation and guidance of injection needle through the vaginal mucosa to the defined injection sites.
The BoNT dosage with respect to the total 200 units administered to each site will be patient specific, determined as the ratio of the resting average resting root-mean square (RMS) value of a specific region divided by the total average resting RMS.
|
Botulinum neurotoxin will be injected into the pelvic floor muscles following either a standard template (standard injection arm), or guided using high-density surface EMG (guided arm).
A personalized, precision botulinum neurotoxin injection guidance medical device, utilizing an intra-vaginal high-density surface EMG system to optimize the treatment outcomes in chronic pelvic pain (CPP) management.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hypertonic metrics of the pelvic muscles defined by intra-vaginal surface EMG
Time Frame: Baseline
|
The pelvic floor hypertonicity will be assessed by evaluating the amplitudes of intra-vaginal high-density surface electromyography recordings.
|
Baseline
|
Hypertonic metrics of the pelvic muscles defined by intra-vaginal surface EMG
Time Frame: 1-Month Post Injection
|
The pelvic floor hypertonicity will be assessed by evaluating the amplitudes of intra-vaginal high-density surface electromyography recordings.
|
1-Month Post Injection
|
Hypertonic metrics of the pelvic muscles defined by intra-vaginal surface EMG
Time Frame: 3-Months Post Injection
|
The pelvic floor hypertonicity will be assessed by evaluating the amplitudes of intra-vaginal high-density surface electromyography recordings.
|
3-Months Post Injection
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Global response assessment
Time Frame: 1-Month Post Injection
|
Compared to prior to the treatment, is the patient very much better, much better, a little better, no change, a little worse, much worse, or very much worse.
|
1-Month Post Injection
|
Global response assessment
Time Frame: 3-Months Post Injection
|
Compared to prior to the treatment, is the patient very much better, much better, a little better, no change, a little worse, much worse, or very much worse.
|
3-Months Post Injection
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urologic Diseases
- Urinary Bladder Diseases
- Pain
- Neurologic Manifestations
- Pregnancy Complications
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Cystitis
- Chronic Pain
- Pelvic Floor Disorders
- Cystitis, Interstitial
- Pelvic Pain
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Cholinergic Agents
- Membrane Transport Modulators
- Acetylcholine Release Inhibitors
- Botulinum Toxins
Other Study ID Numbers
- R44HD107822 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Pain
-
Pain ConcernThe Thistle Foundation; Health and Social Care Alliance Scotland (the ALLIANCE) and other collaboratorsCompletedChronic Pain | Chronic Pain Syndrome | Chronic Pain, Widespread | Chronic Pain Due to Trauma | Chronic Pain Due to Malignancy (Finding) | Chronic Pain Due to Injury | Chronic Pain Post-Procedural | Chronic Pain HipUnited Kingdom
-
Consorci Sanitari de l'Alt Penedès i GarrafRecruitingChronic Post Operative Pain | Chronic Post-surgical Pain | Chronic Knee PainSpain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
University of Alabama, TuscaloosaPatient-Centered Outcomes Research Institute; East Carolina University; Whatley...CompletedPain | Chronic Pain | Chronic Pain Syndrome | Widespread Chronic Pain | Chronic Pain Due to InjuryUnited States
-
University of UtahRecruitingChronic Pain | Chronic Pain Syndrome | Widespread Chronic PainUnited States
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, ChronicTurkey
-
Evolve Restorative CenterFlowonix Medical; Celéri Health, Inc.; Advanced Infusion SolutionsCompletedPain, Chronic | Pain, Intractable | Chronic Nonmalignant PainUnited States
-
Assiut UniversityNot yet recruiting
-
Vastra Gotaland RegionActive, not recruitingPain, Chronic | Widespread Chronic PainSweden
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, Chronic | Video-Assisted Thoracoscopic SurgeryTurkey
Clinical Trials on Botulinum Neurotoxin
-
Evolus, Inc.CompletedGlabellar Frown LinesUnited States
-
Hospital Vall d'HebronAllerganUnknownCerebral Palsy | SialorrheaSpain
-
Seton Healthcare FamilyCompleted
-
AllerganCompleted
-
Abdel-Maguid RamzyCompleted
-
DeNova ResearchCompleted
-
AllerganTerminatedAbdominoplastyUnited States
-
Mentor Worldwide, LLCCompletedSpasmodic TorticollisUnited States
-
Merz Pharmaceuticals GmbHCompleted
-
Mohamed Hayder Oleish SalihCompletedGlabellar Frown Lines | Wrinkle | Facial Expression | RhytidesEgypt